Abstract
The effects of indoramin, a new hypotensive drug with competitive α‐adrenergic receptor blocking properties, were studied in a double‐blind investigation in healthy human subjects. Indoramin (20 mg.) orally produced a significant fall in blood pressure at high exercise loads when compared with placebo. Indoramin (20 and 40 mg.) reduced erect blood pressures during a period of 6 hours when compared with placebo in another double‐blind study. Histamine skin wheals were also reduced in a dose‐related manner but no effect on critical flicker frequency was demonstrated. The pressor response to intravenous norepinephrine showed a parallel time‐related shift to the right after the intravenous administration of 20 mg. of indoramin. The effect of intravenous indoramin (10 mg.) on myocardial funcion was studied with noninvasive techniques. No effect was demonstrated on systolic time intervals, cardiac output, or eiection fraction. Indoramin (20 mg.) given orally twice daily for 2 weeks reduced erect and supine blood pressures without evidence of drug accumulation. No drug‐related effects on biochemical or hematologic values were detected.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
